Financial statements Notes to the consolidated financial statements continued 24.
Bank overdrafts and loans As at 31 December 2016 2015 $m $m Bank overdrafts 10 8 Import and export financing 63 58 Short-term loans 4 Current portion of long-term loans note 28 44 45 117 115 2016 2015 % % The weighted average interest rates paid were as follows: Bank overdrafts 4.32 6.19 Bank loans including the non-current bank loans 3.26 2.77 Eurobond 4.25 4.25 Import and export financing 3.75 3.09 Import and export financing represents short-term financing for the ordinary trading activities of the business, and is mainly denominated in US Dollars, Algerian Dinar, and in Saudi Riyals.
Trade and other payables As at 31 December 2016 2015 $m $m Trade payables 172 139 Accrued expenses 157 122 Other payables 14 15 343 276 Other payables mainly include employees provident fund liability of $5 million 31 December 2015: $5 million, which mainly represents the outstanding contributions to the Hikma Pharmaceuticals Ltd Jordan retirement benefit plan, on which the fund receives 3.5% interest.
Other provisions Other provisions represent the end of service indemnity provisions for employees of certain Hikma Group subsidiaries.
This provision is calculated based on relevant laws in the countries where each Group company operates, in addition to their own policies.
Movements on the provision for end of service indemnity: 2016 2015 $m $m 1 January 28 25 Additions 1 5 Utilisation 2 2 At 31 December 27 28 Hikma Pharmaceuticals PLC 180 172 Hikma Pharmaceuticals plc
